Our study suggests that the inhibition of CX3CR1 expression could be a potential strategy for hypoxia-induced lung disease treatment, and also, to some extent, the activation of innate immunity such as macrophage polarization might be an effective therapeutic target towards PAH disease. Here, CX3CR1 is linked to lung disorder.